XTX Topco Ltd Grows Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Key Points

• XTX Topco Ltd significantly increased its holdings in Y-mAbs Therapeutics by acquiring an additional 70,686 shares, boosting its stake by 340.4% in the first quarter, resulting in ownership of approximately 0.20% valued at $405,000.
• Y-mAbs Therapeutics has received multiple downgrades from analysts, with Canaccord Genuity and Bank of America reducing their price targets to as low as $3.00, reflecting decreased confidence in the company's performance.
• The stock currently has a market capitalization of $385.33 million and an average price target of $11.16, with analysts generally rating it as a "Hold."

XTX Topco Ltd lifted its position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 340.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 91,454 shares of the company's stock after buying an additional 70,686 shares during the quarter. XTX Topco Ltd owned approximately 0.20% of Y-mAbs Therapeutics worth $405,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of YMAB. KLP Kapitalforvaltning AS acquired a new stake in Y-mAbs Therapeutics in the 4th quarter valued at about $46,000. Corton Capital Inc. purchased a new stake in shares of Y-mAbs Therapeutics during the first quarter worth approximately $55,000. ProShare Advisors LLC purchased a new stake in shares of Y-mAbs Therapeutics during the fourth quarter worth approximately $99,000. Wells Fargo & Company MN increased its stake in shares of Y-mAbs Therapeutics by 54.1% during the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock worth $137,000 after buying an additional 6,131 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Y-mAbs Therapeutics by 12.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,818 shares of the company's stock worth $179,000 after buying an additional 2,545 shares during the period. Hedge funds and other institutional investors own 70.85% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on YMAB. Canaccord Genuity Group lowered shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and cut their target price for the stock from $26.00 to $8.60 in a research note on Tuesday, August 5th. Oppenheimer lowered shares of Y-mAbs Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Tuesday, August 5th. Brookline Capital Management lowered shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Jones Trading downgraded Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Finally, Morgan Stanley set a $8.60 price objective on Y-mAbs Therapeutics in a report on Tuesday, August 5th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Y-mAbs Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $11.16.

Y-mAbs Therapeutics Stock Performance

Y-mAbs Therapeutics stock traded up $0.01 during mid-day trading on Wednesday, reaching $8.52. 371,647 shares of the company were exchanged, compared to its average volume of 482,023. Y-mAbs Therapeutics, Inc. has a twelve month low of $3.55 and a twelve month high of $16.11. The firm's 50-day simple moving average is $5.09 and its two-hundred day simple moving average is $4.97. The firm has a market cap of $386.90 million, a PE ratio of -17.03 and a beta of 0.57.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.20. Y-mAbs Therapeutics had a negative return on equity of 24.60% and a negative net margin of 26.03%. The company had revenue of $19.52 million during the quarter, compared to analysts' expectations of $18.40 million. As a group, equities research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.